Evaluation of the ARK Diagnostics immunoassay for qualitative detection of xylazine in urine
Journal of Analytical Toxicology · 13.07.2024 · 48 (6) · 468-471
DOI: 10.1093/jat/bkae043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Analytical Toxicology, online erschienen am 28.05.2024. Verfasst von Patrick B Kyle und 6 weiteren Autor:innen. Beteiligte Einrichtung: Pathology, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216, United States. Hauptthemen laut MEDLINE: Xylazine, Tandem Mass Spectrometry, Substance Abuse Detection. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 12 Literaturangaben.
Abstract (Originalsprache)
Xylazine exposure is common in some US cities, but a commercial assay for routine laboratory testing for xylazine is not currently available. We evaluated a pre-release version of the ARK Diagnostics immunoassay for qualitative detection of xylazine/4-hydroxyxylazine in urine. Studies were conducted using either the semi-quantitative assay application (A. Roche Cobas 503 analyzer) or the qualitative assay application (B. Beckman Coulter AU480 analyzer). Study specimens consisted of deidentified patient urine samples submitted for routine drugs-of-abuse testing. Measurements of xylazine (X) were performed by LC–MS–MS to obtain X-NEGATIVE (X <10 ng/mL) and X-POSITIVE (X ≥10 ng/mL). The semi-quantitative ARK assay was calibrated with a 10 ng/mL cutoff for ARK-POSITVE. For (A): among 74 X-POSITIVE samples, there was 1 ARK-NEGATIVE result (false-negative rate = 1.4%); among 78 X-NEGATIVE samples by LC–MS–MS, there were 0% ARK-POSITIVE results (false-positive rate = 0%). For (B), among 74 X-POSITIVE samples, there were 0 ARK-NEGATIVE results (false-negative rate = 0%); among 78 X-NEGATIVE samples there was 1 ARK-POSITIVE sample (false-positive rate = 1.3%). Common sources of interferences were investigated without evidence of interference. The ARK xylazine/4-OH-xylazine immunoassay was found to be suitable for routine use in screening patient urine samples for presence of xylazine >10 ng/mL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Pathology, University of Mississippi Medical Center, 2500 N State St, Jackson, MS 39216, United States.
- Pathology, Jefferson University Hospital, 117 S 11th St, Philadelphia, PA 19107, United States.
ORCID-Profile: Douglas F Stickle
Zitieren
APA
Kyle, P. B., Mattiello, C. J., Hua, A., Toohey, J. M., Korn, W. R., Saldana-Reed, A., & Stickle, D. F. (2024). Evaluation of the ARK Diagnostics immunoassay for qualitative detection of xylazine in urine. Journal of Analytical Toxicology, 48(6), 468-471. https://doi.org/10.1093/jat/bkae043
Vancouver
Kyle PB, Mattiello CJ, Hua A, Toohey JM, Korn WR, Saldana-Reed A, et al. Evaluation of the ARK Diagnostics immunoassay for qualitative detection of xylazine in urine. Journal of Analytical Toxicology. 2024;48(6):468-471. doi:10.1093/jat/bkae043
BibTeX
@article{Kyle2024,
author = {Kyle, Patrick B and Mattiello, Christopher J and Hua, Albert and Toohey, Joanne M and Korn, Warren R and Saldana-Reed, Alana and Stickle, Douglas F},
title = {Evaluation of the ARK Diagnostics immunoassay for qualitative detection of xylazine in urine},
journal = {Journal of Analytical Toxicology},
year = {2024},
volume = {48},
number = {6},
pages = {468--471},
doi = {10.1093/jat/bkae043}
}
EUVIMED